One year in review: Novelties in the treatment of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 33, Issue 1, 2015, Pages 102-108

  Guidelli, Giacomo M ^a   Barskova, Tatiana ^b   Giuseppina Brizi, M ^a   Lepri, Gemma ^b   Parma, Alice ^c   Talarico, Rosaria ^c   Cantarini, Luca ^a   Frediani, Bruno ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Biosimilar drugs; Clinical trials; Immunogenicity

Indexed keywords

BARICITINIB; BELIMUMAB; BRODALUMAB; DECERNOTINIB; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FILGOTINIB; FOSTAMATINIB; GLUCOCORTICOID; IGURATIMOD; INTERLEUKIN 17; IXEKIZUMAB; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; OCRELIZUMAB; OFATUMUMAB; OLOKIZUMAB; PREDNISONE; SALAZOSULFAPYRIDINE; SARILUMAB; SECUKINUMAB; SIRUKUMAB; TABALUMAB; TACROLIMUS; TOCILIZUMAB; TOFACITINIB; ANTIRHEUMATIC AGENT;

B LYMPHOCYTE; COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MESENCHYMAL STROMA CELL; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; IMMUNOLOGY; JOINT; PATHOLOGY; TIME; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; JOINTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928702759     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. HETLAND ML, JENSEN DV, KROGH NS: Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. Clin Exp Rheumatol 2014; 32 (Suppl. 85): S141-6.
2. CHIU YM, LAI MS, LIN HY et al.: Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration. Clin Exp Rheumatol 2014; 32: 898-903.
3. LóPEZ-GONZáLEZ R, LEóN L, LOZA E, REDONDO M, GARCíA DE YéBENES MJ, CARMONA L: Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin Exp Rheumatol 2015 Jan 20 [Epub ahead of print].
4. WU B, SONG Y, LENG L, BUCALA R, LU LJ: Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol 2015; 33: 20-26.
5. PITSILKA DA, KAFETSIOS K, NIAKAS D: Social support and quality of life in patients with rheumatoid arthritis in Greece. Clin Exp Rheumatol 2015; 33: 27-33.
6. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
7. KITAHAMA M, NAKAJIMA A, INOUE E, TANIGUCHI A, MOMOHARA S, YAMANAKA H: Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate. Mod Rheumatol 2013; 23: 788-93.
8. TANAKA Y, KAWAI S, TAKEUCHI T, YAMAMOTO K, MIYASAKA N: Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. Mod Rheumatol 2013; 23: 1045-52.
9. KANZAKI T, KAWAHATA K, KANDA H, FUJIO K, KUBO K, AKAHIRA L: Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis. Rheumatol Int 2013; 33: 871-7.
10. KANG KY, JU JH, SONG YW, YOO DH, KIM HY, PARK SH: Tacrolimus treatment increases bone formation in patients with rheumatoid arthritis. Rheumatol Int 2013; 33: 2159-63.
11. KIRWAN JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333: 142-6.
12. den UYL D, ter WEE M, BOERS M et al.: A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014; 73: 1071-8.
13. SADRA V, KHABBAZI A, KOLAHI S, HAJIALILOO M, GHOJAZADEH M: Randomized double-blind study of the effect of dexamethasone and methylprednisolone pulse in the control of rheumatoid arthritis flare-up: a preliminary study. Int J Rheum Dis 2014; 17: 389-93.
14. de JONG PH, HAZES JM, HAN HK, HUISMAN M, van ZEBEN D, van der LUBBE PA: Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014; 73: 1331-9.
15. VERSCHUEREN P, De COCK D, CORLUY L, JOOS R, LANGENAKEN C, TAELMAN V: Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 2015; 74: 27-34.
16. SCOTT DGI: Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol 2014; 43: 470-6.
17. ISHIGURO N, YAMAMOTO K, KATAYAMA K et al.; Iguratimod-ClinicICal Study Group: Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 2013; 23: 430-9.
18. HARA M, ISHIGURO N, KATAYAMA K et al.; Iguratimod-ClinicICal Study Group: Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 2014; 24: 410-8.
19. TANAKA Y, TAKEUCHI T, AMANO K et al.: Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Mod Rheumatol 2014; 24: 399-404.
20. TANAKA Y, MARTIN MOLA E: IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis 2014; 73: 9.
21. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
22. GENOVESE MCFR, FIRST D, JANSSEN N et al.: Efficacy and safety of olokizumab in rheumatoid arthritis patients with an inadequate response to TNF inhibitor therapy: outcomes of a randomized phase IIb study. Ann Rheum Dis 2014; 73: 1607-15.
23. HUIZINGA TWFR, JASSON M, RADIN AR et al.: Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014; 73: 1626-34.
24. SMOLEN JS, ZHUANG Y, SHEN S et al.: Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomized, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2014; 73: 1616-25.
25. GENOVESE MC, DUREZ P, RICHARDS HB et al.: One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 2014; 41: 414-21.
26. STRAND, V, KOSINSKI M1, GNANASAKTHY A, MALLYA U, MPOFU S: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. Health Qual Life Outcomes 2014; 12: 31.
27. GENOVESE MC, GREENWALD M, CHO CS et al.: A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheum 2014; 66: 1693-704.
28. MARTIN DA, CHURCHILL M, FLORES-SUAREZ L et al.: A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013.
29. GENOVESE MC, BOJIN S, BIAGINI IM et al.: Tabalumab in rheumathoid arthritis patients with an inadequate response to methotrexate and naïve to biologic therapy. Arthritis Rheum 2013; 65: 880-9.
30. FLEISCHMANN R, CUTOLO M, GENOVESE MC et al.: Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate responsetodisease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64: 61729.
31. KREMER JM, COHEN S, WILKINSON BE et al.: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64: 970-81.
32. van VOLLENHOVEN RF, FLEISCHMANN R, COHEN S et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N Engl J Med 2012; 367: 508-19.
33. Van der HEIJDE D, TANAKA Y, FLEISCH-MANN R et al.: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-70.
34. BURMESTER GR, BLANCO R, CHARLES-SCHOEMAN C et al.: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60.
35. LEE EB, FLEISCHMANN R, HALL S et al.; ORALoral Start Investigators: Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-86.
36. FEIST E, BURMESTER GR: Small molecules targeting JAKs-a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013; 52: 1352-7.
37. van der HEIJDE D, TANAKA Y, FLEISCHMANN R et al.: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-70.
38. WEINBLATT ME, GENOVESE MC, HO M et al.: Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase iii, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol 2014; 66: 3255-64.
39. LEE EB, FLEISCHMANN R, HALL S et al.; ORALoral Start Investigators: Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-86.
40. BERHAN A: Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies. BMC Musculoskelet Disord 2013; 14: 332.
41. GENOVESE MC, van der HEIJDE DM, KEYSTONE EC et al.: A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist. J Rheumatol 2014; 41: 2120-8.
42. WANG L, WANG L, CONG X et al.: Human umbilicalcord mesenchymal stem cell therapy for patients with activerheumatoid arthritis: safety and efficacy. Stem Cells Dev 2013; 22: 3192-202.
43. ALVARO-GRACIA JM, JOVER JA, GARCIA-VICUñA R et al.: Phase Ib/IIa study on intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis patients. In: Abstract at the Annual Scientific Meeting ACR; 2013.